Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APP heparin manufacturing facility approved

Executive Summary

APP Pharmaceuticals announces Aug. 18 that FDA approved a facility in Barceloneta, Puerto Rico for the manufacture of three product codes of Heparin Sodium Injection. Currently the sole supplier of heparin in the U.S. in the wake of Baxter's heparin contamination fiasco, APP said approval of the third manufacturing facility will free up its other facilities to fulfill outstanding orders. The German health care products and services company Fresenius announced last month a $4.6 billion acquisition of APP - a buyout price that could increase if APP profits are higher than projected (1"The Pink Sheet," July 14, 2008, p. 17)

You may also be interested in...



Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.

India Approves 16 Applications Under PLI Scheme

India has approved a $46m project by giving the green light to 16 drug production applications under the Production Linked Incentive scheme. The government has ordered the setting up and commercial production of the 16 projects to commence immediately. 

China Cancer Drug Off-Label Use: A Crossed Line?

Off-label use of cancer drugs in China is legal and even common in certain cases. But a line has been crossed in cases of active promotion and even conflicts of interest for some high-priced products and unproven cell therapies, unveiled by a Chinese physician whistleblower, regulatory observers say.

UsernamePublicRestriction

Register

PS050012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel